Navigation Links
AbbVie Issues Inaugural Full-Year Outlook for 2013
Date:1/30/2013

and the advancement of key development programs, including the start of Phase III studies for our interferon-free Hepatitis C (HCV) combination and elagolix.

AbbVie expects long-term growth will be fueled by a compelling pipeline of therapies in development to address medical conditions with high unmet need.  The company is focused on advancing a number of Phase III programs, including: an interferon-free oral combination for HCV; daclizumab for relapsing remitting multiple sclerosis (in partnership with Biogen); elagolix for endometriosis; elotuzumab for multiple myeloma (in partnership with Bristol Myers Squibb); and several new indications for HUMIRA.

In 2013, the company expects to initiate several Phase III programs including atrasentan for diabetic kidney disease and ABT-199 in chronic lymphocytic leukemia (CLL).  Additionally, AbbVie is planning Phase IIB starts for: elagolix in uterine fibroids; our partnered JAK1 inhibitor (GLPG0634) for rheumatoid arthritis (RA); BT-061 for RA; and ABT-719 for acute kidney injury associated with major cardiac and other surgeries.  Finally, in 2013, the company intends to present data from a number of key development programs, including our rapidly advancing HCV program, oncology, renal disease, immunology and Alzheimer's disease.

Management to Discuss Company Performance and Outlook on Investor Call TodayAbbVie will host an investor conference call today at 8 a.m. Central time to discuss our fourth-quarter and full-year 2012 highlights and 2013 outlook. Participating on the call will be Rick Gonzalez , chairman and chief executive officer; Bill Chase , executive vice president and chief financial officer; Laura Schumacher , executive vice president of business development, external affairs and general counsel; John Leonard , senior vice president and chief scientific o
'/>"/>

SOURCE AbbVie
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AbbVie Named to S&P 500 Dividend Aristocrat Index
2. Emmaus Life Sciences Issues Statement in Response to Announcement by AFH Holding & Advisory
3. Qualitest Issues Voluntary, Nationwide Recall of 101 Lots of Hydrocodone Bitartrate and Acetaminophen Tablets, USP 10 mg/500 mg Due to the Potential for Oversized Tablets
4. Fero Industries, Inc. Issues Corporate Update
5. CSL Behring Parent Company, CSL Limited, Issues Fourth Corporate Responsibility Report
6. Ranbaxy Issues Voluntary Nationwide Recall of 41 lots of Atorvastatin Calcium Tablets 10 mg, 20 mg and 40 mg Due to Potential Presence of Foreign Substance
7. Emmaus CEO Yutaka Niihara, M.D., Issues Statement In Connection with Status of Companys Phase III FDA Sickle Cell Treatment Trials
8. Zi Xiu Tang Success, LLC Issues Voluntary Nationwide Recall of Classic Zi Xiu Tang Bee Pollen Capsules and Ultimate Formula Capsules due to Undeclared Sibutramine
9. CORRECTION: Star Scientific Issues Statement Correcting the Underreporting of the "Flint" CRP Human Study Results
10. Qualitest Issues Voluntary, Nationwide Recall for One Lot of Hydrocodone Bitartrate and Acetaminophen Tablets, USP 10 mg/500 mg Due to the Potential for Oversized Tablets
11. Sun Pharmaceutical Industries, Inc. Issues Nationwide Voluntary Recall of One Lot of Nimodipine Capsules due to Crystallization of the Fill Material
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... FRANCISCO, Calif. , Aug. 3, 2015 /PRNewswire/ ... the treatment of cancer, today announced the promotion ... Debanjan Ray , who previously served ... management, has been promoted to senior vice president ... CytomX, Mr. Ray held positions as the vice ...
(Date:8/3/2015)... OSAKA, Japan and FLORHAM PARK, ... today announced that once-daily naldemedine met its primary and ... for the treatment of opioid-induced constipation (OIC) in adult ... oral, peripherally acting mu-opioid receptor antagonist (PAMORA). This is ... its primary and key secondary endpoints. Study ...
(Date:8/3/2015)... Inc. (PK:ECIA), a medical device company owning patented surgical ... invasive surgery, today announced financial results for its fiscal ... The Company posted quarterly net revenue of $2.454 ... or $(0.02) per share. These results compare to net ... $202 thousand, or $(0.02) per share, in the year-ago ...
Breaking Medicine Technology:CytomX Announces Management Team Promotions 2CytomX Announces Management Team Promotions 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4Encision Reports First Quarter Fiscal Year 2016 Results 2Encision Reports First Quarter Fiscal Year 2016 Results 3Encision Reports First Quarter Fiscal Year 2016 Results 4Encision Reports First Quarter Fiscal Year 2016 Results 5
... , ST. LOUIS , Feb. 8 ... its first Stereotaxis Magnetic Navigation System in Taiwan at ... a Grand Opening event on January 26 that received ... been successfully performed using Stereotaxis at the hospital. , "All too ...
... Md. , Feb. 8 Novavax, Inc. (Nasdaq: ... to discontinue negotiations in its pursuit of the previously announced ... Novavax,s virus-like-particle (VLP)-based vaccines against influenza in the country of ... inability to agree on acceptable terms of the proposed collaboration ...
Cached Medicine Technology:Stereotaxis Installs First System in Taiwan 2Stereotaxis Installs First System in Taiwan 3Novavax Terminates Negotiations with ROVI Pharmaceuticals for Influenza Vaccine Collaboration 2Novavax Terminates Negotiations with ROVI Pharmaceuticals for Influenza Vaccine Collaboration 3Novavax Terminates Negotiations with ROVI Pharmaceuticals for Influenza Vaccine Collaboration 4
(Date:8/3/2015)... ... August 03, 2015 , ... Hub International Insurance ... Williams has joined its growing California employee benefits division. Mr. Williams will ... his clients. Mr. Williams will be joining the newly integrated Northern California employee ...
(Date:8/3/2015)... ... August 03, 2015 , ... Foot and Ankle Specialists of ... podiatrist, creating the largest medical practice in the Mid-Atlantic region – and the second ... 21 locations with 33 doctors. , Dr. Hetal Kathrotiya-Mago is a Maryland native. She ...
(Date:8/3/2015)... ... ... Did you know that there are thousands of Seniors or Elderly ... options which A-1 Home Care Agency specialize in? In fact, diversity, multi-cultural, financing options, ... Care Agency is known for. , With all the Los Angeles ...
(Date:8/2/2015)... Ky. (PRWEB) , ... August 03, 2015 , ... A ... recurrence of some childhood cancers. The study is led by Kenneth G. Lucas, ... the University of Louisville in collaboration with colleagues at Kosair Children’s Hospital ...
(Date:8/2/2015)... Raleigh, NC (PRWEB) , ... August 02, 2015 , ... ... be a powerful prognostic indicator for mesothelioma. Surviving Mesothelioma has just posted an article ... at the University of New South Wales tested for Ki67 expression in tissue samples ...
Breaking Medicine News(10 mins):Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 2Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 3Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 4Health News:A-1 Home Care in Los Angeles and Orange County Honors Exceptional Office Staff 2Health News:A-1 Home Care in Los Angeles and Orange County Honors Exceptional Office Staff 3Health News:UofL Physicians Conducting Vaccine Trial for Children with Relapsed Tumors at Kosair Children’s Hospital 2Health News:Scientists Link Protein Marker with Mesothelioma Prognosis in New Study, According to Surviving Mesothelioma 2
... to be hurt from physical injuries such as a fall or ... ,The University of Queensland study found any alcohol consumption quadrupled ... alcohol and this risk remained at 2.5 times that of a ... and specific drinks such as beer or spirits did not increase ...
... a threefold risk of premature death, according to a new ... Internal Medicine.// , Lead researcher, Dr. Frank B. ... Harvard School of Public Health says, “This study underscores the ... for children, but increases the risk for death in adulthood." ...
... health lecturers Mary Seddon and Alan Merry there is ... were victims of preventable medical errors. ,The ... Journal mainly focused on how careless attitudes of the ... suffering adverse events. Statistics show that more than 1500 ...
... health alert after 15 people died of Japanese encephalitis ... in the past two weeks, officials said.// ,An ... epidemic proportions in the four districts of Jorhat, Dibrugarh, ... hit by the disease. ,"We have ...
... absence of an AIDS policy action, the potential economic cost ... Development Programme (UNDP) report.// ,"The potential costs to the ... HIV epidemic could be quite high," according to the report ... the National Council of Applied Economic Research (NCAER) with the ...
... children does not merit the prescription of antibiotics, researchers ... if the child's condition worsens. Antibiotics are known to ... every small pretext, has led to the rise of ... defeat even the most potent antibiotics. When researchers prescribed ...
Cached Medicine News:Health News:Alcohol Drinkers Prone to Physical Injuries 2Health News:Risk Of Premature Death In Obese Adolescents 2Health News:Risk Of Premature Death In Obese Adolescents 3Health News:HIV Epidemic Can Slow Down Economic Growth: UNDP 2
... monitor offers a comprehensive array of features ... pediatric and neonate patients, to magnetic resonance ... is the first MR monitor designed to ... neonate patient monitoring. The new monitor is ...
... specific antigen (PSA) is a serine protease that ... epithelial cells of the acini and ducts. Normal ... 0.1-2.6 ng/mL. Reports have suggested that elevated level ... must useful tumor markers in diagnosis of prostate ...
... in vitro assay for detection of alpha ... is a protein with molecular mass ranging ... concentration in serum is below 9 ng/mL; ... ovarian, testicular and presacral teratocarcinomas, and other ...
The IDS Gamma-B 25-Hydroxy Vitamin D kit is a conventional liquid phase radioimmunoassay intended for the quantitative determination of 25-hydroxy vitamin D (25-OHD) and other hydroxylated metabolite...
Medicine Products: